-+ 0.00%
-+ 0.00%
-+ 0.00%

Sarepta says ELEVIDYS shows 2-year functional gains in 8-12-year-old Duchenne patients versus external controls at WMS 2026

PUBT·09/30/2026 12:33:25
Sarepta says ELEVIDYS shows 2-year functional gains in 8-12-year-old Duchenne patients versus external controls at WMS 2026
  • Sarepta presented new ELEVIDYS data at the 2026 World Muscle Society annual congress, citing functional benefits in older ambulatory Duchenne patients.
  • Two-year follow-up in boys treated at ages 8-12 showed sustained functional performance versus a matched external control, suggesting slower disease progression.
  • Separate results already shown for children treated at ages 2 to under 3 indicated strong biological drug activity soon after infusion.
  • Safety remained consistent with the established profile, with no new safety signals reported across these analyses.
  • Use in patients under age 4 remains investigational, with longer-term functional outcomes in the youngest group still being tracked.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300830BIZWIRE_USPR_____20260930_BW354567) on September 30, 2026, and is solely responsible for the information contained therein.